Navigation Links
Pharmaceutics International, Inc. (Pii) Successfully Completes EMA and FDA Inspection

HUNT VALLEY, Md., Aug. 18, 2011 /PRNewswire/ -- Pharmaceutics International, Inc. (Pii), a leading contract development and manufacturing organization, today announced it has successfully completed the first-ever US-based joint European Medicines Agency (EMA) and Food and Drug Administration (FDA) inspection.  

"Our entire team is very proud of the successful outcome of the joint FDA/EMA inspection," said Tony Horton, vice president of quality assurance at Pii. "This achievement validates our commitment to continuous improvement and our ability to continue to meet the requirements of the FDA, EMA and other international regulatory agencies."

The rigorous four day inspection was conducted by representatives for the EMA from the Medicines and Healthcare products Regulatory Agency (MHRA) and Medical Products Agency of Sweden (MPA) and from the FDA. The inspection is part of the FDA and EMA joint initiative, which focuses on increasing international regulatory collaboration among the agencies in order to enhance global drug quality and safety.  

As part of the inspection, Pii's clients received EMA marketing authorization for a soft gel product and reauthorization for a tablet product. Additionally, during the audit the FDA performed an inspection of the company's quality systems as a follow up to its December 2010 inspection for four Pre Approval Inspections. Both FDA inspections have been closed as of June 2011, indicating that Pii is in substantial compliance with US GMPs.

"We are extremely pleased to have achieved this major regulatory milestone," said Steve King, senior vice president of Pii. "This approval allows Pii to continue providing commercial manufacturing services to the global pharmaceutical industry. We look forward to working with our clients to bring several other products to market."

About Pharmaceutics International, Inc.

Pharmaceutics International, Inc. (Pii) is a privately held Drug Delivery Solutions company providing dosage form development and GMP Manufacturing services to the global pharmaceutical industry. Pii's vision is to become the benchmark in pharmaceutical product development outsourcing. Headquartered in Hunt Valley Maryland USA with European facilities in the UK, Pii offers preformulation testing, formulation development and clinical trial material and commercial manufacture of parenteral, solid, semi-solid and liquid dosage forms. For further information about Pii visit

Elizabeth Hickman, Marketing Manager
Pharmaceutics International, Inc.
10819 Gilroy Road
Hunt Valley, MD 21031
Phone: (443) 858-0768

SOURCE Pharmaceutics International, Inc. (Pii)
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
2. Pharmaceutics International Inc. (Pii) Announces Appointment of Rampurna Prasad Gullapalli, Ph.D. as Vice President of Drug Delivery Technologies
3. Pharmaceutics International, Inc. (Pii) Expands Drug Formulation and Manufacturing Capabilities with Hot Melt Extrusion Technology
4. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
5. Medizone International, Inc. (MZEI.PK): Trials of the AsepticSure Hospital Sterilization System Have Begun
6. Chindex International, Inc. to Report Second Quarter Fiscal 2010 Financial Results
7. Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results
8. Natural Alternatives International, Inc. Announces Filing of Patent Infringement Lawsuit
9. DATATRAK International, Inc. Announces Year-End Backlog
10. New Database from ANSI, AAMI, ASTM International, and DIN Provides Centralized Source of Information for Medical Device Professionals
11. DAVISCO Foods International, Inc. and MEGGLE Group Announce a Joint Venture for the Production of Pharmaceutical Lactose.
Post Your Comments:
(Date:11/27/2015)... , Pays-Bas, November 27, 2015 ... au traitement photodynamique au Bremachlorin contre le cancer ... approche consistant à combiner l,immunothérapie au traitement photodynamique ... --> Une nouvelle approche consistant ... contre le cancer avancé.    ...
(Date:11/27/2015)... 2015 --> ... online. The potential to save costs, improve treatment quality ... from fully exploited as yet. Here, particular emphasis is ... via mobile tablet or directly at the patients, bedside. ... ) -->      (Photo: ...
(Date:11/27/2015)... Ein neuer Kombinationsansatz vereint ... --> Ein neuer Kombinationsansatz vereint Immuntherapie ... --> Ein neuer Kombinationsansatz vereint Immuntherapie ... Clinical Cancer Research vom 6. November ... vom 6. November 2015 berichtet. --> ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... The rapid speed at ... people age, more care is needed, especially with Alzheimer’s, dementia and other cognitive ... being overworked. The forgotten part of this equation: 80 percent of medical care ...
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss ... to treat it. Surviving Mesothelioma has just posted the findings on the website. ... Zurich analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy followed ...
(Date:11/27/2015)... ... 27, 2015 , ... An inventor, from Hopkinsville, Ky., thought ... at home, so he invented the patent-pending ELECTRONIC M.D. , The ELECTRONIC M.D. ... doing so, it could help to prevent potential overdose situations. As a result, ...
(Date:11/27/2015)... ... 2015 , ... "When I was traveling, I was very ... "Many people catch diseases simply from sitting on such dirty toilet seats. I ... germs." , He developed the patent-pending QUDRATECS to eliminate the need to sit ...
(Date:11/27/2015)... County, CA (PRWEB) , ... November 27, 2015 , ... ... season , The company is offering customers 10% off of their purchase of lice ... any treatment at full price. According to a company spokesperson. “Finding lice is a ...
Breaking Medicine News(10 mins):